Filing search / Inhibrx Biosciences, Inc. / "Satisfaction"

8-K

INBX Inhibrx Biosciences, Inc.

24 May 24

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

4:08pm

to the satisfaction or waiver of customary closing conditions. Beginning on May 28, 2024 and through the Distribution Time, there are expected

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

24 May 24

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

4:08pm

to the satisfaction or waiver of certain customary closing conditions. Upon closing of the transactions, Inhibrx’s common stock will be delisted from … by such statements. Such risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing

DEFA14A

INBX Inhibrx Biosciences, Inc.

20 May 24

Additional proxy soliciting materials

9:48pm

expressed or implied by such statements. Such risks and uncertainties include, among other things, risks related to the satisfaction or waiver

8-K

INBX Inhibrx Biosciences, Inc.

17 May 24

Other Events

5:29pm

include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure

DEFA14A

INBX Inhibrx Biosciences, Inc.

17 May 24

Additional proxy soliciting materials

4:25pm

or implied by such statements. Such risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions

8-K

EX-99.1

ox9 j4ut0mu0ehqu

9 May 24

Inhibrx Reports First Quarter 2024 Financial Results

4:08pm

8-K

EX-99.1

anl7x99

8 May 24

Other Events

4:42pm

DEFM14A

6por zne320b

26 Apr 24

Proxy related to merger

4:06pm

DEFA14A

mwyxvh8

12 Mar 24

Additional proxy soliciting materials

4:05pm

8-K

corwd4 qw52a

12 Mar 24

Other Events

4:02pm

8-K

EX-99.1

8rcxbi9tv lixra7z

28 Feb 24

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

9:12am

DEFA14A

3d6unohjv 9oibjupjxb

6 Feb 24

Additional proxy soliciting materials

4:30pm

DEFA14A

ms5jlu19gwjvesdos

23 Jan 24

Additional proxy soliciting materials

5:25pm

DEFA14A

0sq8 cyhso315vusr

23 Jan 24

Additional proxy soliciting materials

6:38am

8-K

EX-99.1

ic45e0z2st07jam6

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

lcicj45y

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.1

mkx2200upv3 wme7

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.2

8vh9m2q y0n

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am